
CRISIL Share Price Falls 0.77% After Q1 Results Announced on 22 July 2026
CRISIL CMP Rs 4460.6, -0.77% as of 23 Jul 2026. Q1 FY27 results announced 22 July 2026. PAT Rs 216 crore, +26.2% YoY. Revenue Rs 1097 crore, +26.5% YoY.
Updated: 23 Jul 2026 • 10:37 am
Posted by:

CRISIL share price fell 0.77% to trade at Rs 4460.6 as of 23 July 2026, after the company announced its Q1 FY27 results on 22 July 2026.
The company reported revenue of Rs 1097 crore, up 26.5% year on year and a net profit of Rs 216 crore, up 26.2% year on year for the quarter ended 30 June 2026.
Click Here – Get Free Investment Predictions
CRISIL Q1 FY27 Results Snapshot
| Metric | Q1 FY26 | Q1 FY27 | YoY Change |
|---|---|---|---|
| Revenue | Rs 867 Cr | Rs 1097 Cr | +26.5% |
| Net Profit (PAT) | Rs 172 crore | Rs 216 crore | +26.2% |
CRISIL is a ratings & research company listed on the Indian stock exchanges. Broad based growth across ratings, research and analytics segments
Learn More About Univest, a SEBI Registered Investment Advisor
Why CRISIL Moved After Q1 Results
Profit growth of 26.2% year on year gave the stock a fundamental tailwind. Revenue grew a strong 26.5% year on year, reflecting healthy underlying business momentum.
Trading volumes in CRISIL were also elevated around the results announcement, a typical pattern when a stock re-rates on fresh quarterly numbers rather than moving purely on broader index cues. Investors reading the print alongside sector peers get a fuller picture of whether the move is company specific or part of a wider sector trend.
Broader Market Context
The reaction in CRISIL shares also comes against a backdrop of a broader Indian market that has been volatile this week, with global cues including rising crude oil prices on US-Iran tensions and a weak yen weighing on sentiment across sectors. Stock specific results commentary should be read alongside this wider market context rather than in isolation.
Sector peers of CRISIL in the ratings & research space have also seen mixed reactions this results season, underlining that stock specific execution and margin trends are driving individual outcomes more than broad sector sentiment alone.
Download the Univest iOS App or Univest Android App to track CRISIL live price and get daily stock recommendations.
What Investors Should Watch Next
Investors tracking CRISIL should watch for management commentary on the post-results earnings call, any changes in brokerage ratings or price targets, and the stock’s technical support and resistance levels in the sessions following results.
Use the Univest Screener to compare CRISIL against sector peers on valuation and growth metrics before making any investment decision. Longer term investors may also want to track how the company’s guidance for the rest of FY27 evolves over the coming quarters.
Conclusion
CRISIL fell 0.77% following its Q1 FY27 results announced on 22 July 2026. Profit growth of 26.2% year on year gave the stock a fundamental tailwind. Investors should track further brokerage commentary and the company’s next quarterly update, and consult a SEBI-registered advisor before making any investment decision.
Investors should keep watching CRISIL share price action closely in the sessions ahead as more brokerage commentary comes in following the results.
Investors should keep watching CRISIL share price action closely in the sessions ahead as more brokerage commentary comes in following the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on CRISIL After Q1 Results
Why did CRISIL share price fall after Q1 results?
Ans. CRISIL fell 0.77% following its Q1 FY27 results announced on 22 July 2026. Profit growth of 26.2% year on year gave the stock a fundamental tailwind.
What was CRISIL’s Q1 FY27 profit figure?
Ans. CRISIL reported a net profit of Rs 216 crore in Q1 FY27, up 26.2% year on year.
What was CRISIL’s Q1 FY27 revenue?
Ans. CRISIL reported revenue of Rs 1097 crore in Q1 FY27, up 26.5% year on year.
When did CRISIL announce its Q1 FY27 results?
Ans. CRISIL announced its Q1 FY27 results on 22 July 2026, for the quarter ended 30 June 2026.
What is the current price of this stock?
Ans. CRISIL was trading at Rs 4460.6 as of 23 July 2026, down 0.77% for the session.
Should I buy this stock after the Q1 results reaction?
Ans. This article is for informational purposes only and is not investment advice. Investors should evaluate the results in the context of their own portfolio and consult a SEBI-registered investment advisor before making any investment decision.
Where can I track live price and updates?
Ans. Investors can track CRISIL’s live share price, Q1 FY27 results details and analyst commentary on the Univest platform.
Recent Articles

Indoco Remedies vs Alkem Laboratories Business Model: Which Domestic Branded Formulations Wins
23 July 2026

Tanla Platforms Ltd. (TANLA) Share Price Surges 14.04% Today
23 July 2026

ITC Hotels vs EIH Limited Business Model: Which Hotels and Hospitality Wins
23 July 2026

ABSL Dynamic Bond Direct Quarterly IDCW: NAV Today, Performance Review and Should You Invest?
23 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Indoco Remedies vs Alkem Laboratories Business Model: Which Domestic Branded Formulations Wins
Tanla Platforms Ltd. (TANLA) Share Price Surges 14.04% Today
ITC Hotels vs EIH Limited Business Model: Which Hotels and Hospitality Wins
ABSL Dynamic Bond Direct Quarterly IDCW: NAV Today, Performance Review and Should You Invest?
Mankind Pharma vs Ajanta Pharma Business Model: Which Domestic Branded Formulations Wins
Popular this week
Indoco Remedies vs Alkem Laboratories Business Model: Which Domestic Branded Formulations Wins
Tanla Platforms Ltd. (TANLA) Share Price Surges 14.04% Today
ITC Hotels vs EIH Limited Business Model: Which Hotels and Hospitality Wins
ABSL Dynamic Bond Direct Quarterly IDCW: NAV Today, Performance Review and Should You Invest?
Mankind Pharma vs Ajanta Pharma Business Model: Which Domestic Branded Formulations Wins

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





